Skip to main content
. 2017 Apr 28;8(28):46436–46448. doi: 10.18632/oncotarget.17502

Figure 2. Hazard ratios (HR) for kidney failure for patients with versus without cellular/fibrocellular crescents.

Figure 2

The IgAN patients with crescents had an increased risk of worse kidney outcome (C0 as reference; HR, 1.93; 95% CI, 1.49-2.50; P < 0.001), with no evidence of heterogeneity (I2 = 40.9%; P = 0.076).